Why many choline alfoscerates accepted price cuts
By Lee, Tak-Sun | translator Kim, Jung-Ju
23.09.05 06:35:05
가나다라
0
Price of 80% of capsule formulations was cut due to contract manufacture...includes many blockbusters
Selective reimbursement and clinical reevaluations increase the risk, reflecting the low-price strategy taken by companies due to competition between products
▲Pic Chongkundang Gliatirin Soft Cap (left) and Gliatamin(right), leading choline alfoscerate drugs
Companies are reluctant to self-manufacture their brain function enhancer choline alfoscerates despite price cuts.Only 20% of the companies decided to protect their drug price by switching to self-manufacture, and the prices of the others that opted to continue manufacturing through contract manufacture organizations (CMOs) were cut.
This fact was evident in the insurance price ceiling reevaluation results announced by the Ministry of Health and Welfare on the 1st.
Among the 51 choline alfoscerate 0.4g capsule formulations, 40 of them received price cuts of up to 15% of the highest price (KRW 445/capsule).
11 products have maintained the original drug pr
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)